There isn't any guarantee that the company will be a good investment on the force or direction of those trends alone. But ...

Clinical trials of single-agent targeted drugs have shown limited efficacy. In the only trial of single-agent immunotherapy ...

A risk stratification algorithm may be able to predict which patients with advanced chronic liver disease are at risk of ...

As we start looking to the year ahead, the pharma industry is gearing up for a slate of new drug launches and U.S. Food and ...

Researchers analyzed US-based phase 1-3 cancer treatment trials registered on ClinicalTrials.gov from 2017 to 2022.

Fintel reports that on October 25, 2024, Citigroup downgraded their outlook for Bristol-Myers Squibb (NYSE:BMY) from Buy to ...

Expectations for Bristol Myers Squibb's Q3 results have significantly declined. Despite this, check out why I maintain a "Buy ...

Equities researchers at Leerink Partnrs decreased their Q3 2024 EPS estimates for Bristol-Myers Squibb in a research report ...

Big Pharma is in federal appeals court making the absurd argument that Medicare shouldn’t be able to negotiate drug prices, a ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) is scheduled to be issuing its quarterly earnings data before the market ...

Key scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology Evotec ...

Evotec announced in May of 2022 that the Company has further extended and expanded its partnership with Bristol Myers Squibb for another 8 years as the initial collaboration proved to be highly ...